Previously Taboo Drugs Presenting New (and Ancient) Solutions to Rising Depression, Anxiety Cases

Facing a rising tide of despair, and waves of anxiety and depression cases, new solutions are being sought in the mental health field—including some that until recently were seen as taboo and illicit. While Prozac from Eli Lilly (NYSE:LLY) continues to reign among the top-prescribed options to fight depression, even the New York Times is beginning to discuss a shift away from the Prozac era of antidepressant drugs. This shift includes new medicinal options derived from previously illicit ingredients, such as the ketamine-based Spravato from Johnson & Johnson (NYSE:JNJ), and other more natural solutions involving psilocybin mushrooms or cannabis such as those from innovators like The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF) and Canopy Growth Corp. (NYSE:CGC) (TSX:WEED). Vancouver-based trendsetters The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF) have been leading the way as of late, with a series of moves in the direction of medicinal mushrooms. The latest announcement from the company was regarding it’s newly created subsidiary Flourish Mushroom Labs Inc., ... Click here to view full article